TwitterLinkedInFacebook Instagram
United StatesLanguage Flag

Press Release

OraSure Technologies to Present at Thomas Weisel Partners' Healthcare Tailwinds 2005 Conference

August 25, 2005 at 6:01 AM EDT

BETHLEHEM, Pa., Aug 25, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, and Ronald H. Spair, Chief Financial Officer, will speak to the investment community at the Thomas Weisel Partners' Healthcare Tailwinds 2005 Conference in Boston, Massachusetts, at approximately 10:55 am Eastern Time (7:55 am Pacific Time) on September 7, 2005. The conference will be simultaneously webcast over the Internet.

Interested investors can access the live audio webcast of the discussion by going to OraSure Technologies' web site, www.orasure.com, and clicking on the Investor Information link. A replay of the audio webcast will be available until September 14, 2005, on OraSure Technologies' web site.

About OraSure Technologies

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral fluid collection devices and assays to the life insurance industry and public health markets for the detection of antibodies to HIV. In addition, the Company supplies oral fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to www.orasure.com.

SOURCE: OraSure Technologies, Inc.

OraSure Technologies, Inc.
Ronald H. Spair, 610-882-1820
Investorinfo@orasure.com

© OraSure Technologies., 2024